U.S. Clinical Oncology Next Generation Sequencing Market
The clinical oncology next generation sequencing market in the United States is expected to reach a projected revenue of US$ 711.8 million by 2033. A compound annual growth rate of 16.03% is expected of the United States clinical oncology next generation sequencing market from 2026 to 2033.
- Biotechnology
- Sequencing technology
- clinical oncology next generation sequencing ngs market
- Sequencing technology
Revenue, 2025 (US$M)
$218.0
Estimate, 2026 (US$M)
$251.4
Forecast, 2033 (US$M)
$711.8
CAGR, 2026 - 2033
16.0%
Global Market
Related Markets
Ask Prism AI anything about the clinical oncology next generation sequencing ngs market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
Every answer starts with GVR research, and every figure is cited.Explore Prism AI
U.S. clinical oncology next generation sequencing market highlights
- The U.S. clinical oncology next generation sequencing market generated a revenue of USD 218.0 million in 2025 and is expected to reach USD 711.8 million by 2033.
- The U.S. market is expected to grow at a CAGR of 16.03% from 2026 to 2033.
- In terms of segment, targeted sequencing and resequencing was the largest revenue generating technology in 2025.
- Whole Genome Sequencing is the most lucrative technology segment registering the fastest growth during the forecast period.
Clinical oncology next generation sequencing market data book summary
| Market revenue in 2025 | USD 218.0 million |
| Market revenue in 2033 | USD 711.8 million |
| Growth rate | 16.03% (CAGR from 2026 to 2033) |
| Largest segment | Targeted sequencing and resequencing |
| Fastest growing segment | Whole Genome Sequencing |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Whole Genome Sequencing, Targeted Sequencing and Resequencing, Whole Exome Sequencing |
| Key market players worldwide | Illumina Inc, Thermo Fisher Scientific Inc, Roche, Agilent Technologies Inc, Myriad Genetics Inc, PerkinElmer, Roche Holding AG, Pacific Biosciences of California Inc, Oxford Nanopore Technologies PLC, Paradigm Healthcare, Eurofins Scientific SE, Qiagen NV |
Other key industry trends
- In terms of revenue, U.S. accounted for 39.0% of the global clinical oncology next generation sequencing market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. clinical oncology next generation sequencing market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 75.4 million by 2033.
No credit card required*
Publish Date: Jul 09, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Clinical Oncology Next Generation Sequencing Ngs Market
Clinical oncology next generation sequencing ngs market segmentation & scope
Clinical Oncology Next Generation Sequencing Ngs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Myriad Genetics Inc | View profile | 2,700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | www.myriad.com |
| Paradigm Healthcare | View profile | 11-50 | San Francisco, California, United States, North America | paradigm-healthcare.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
| PerkinElmer | View profile | 10001+ | Waltham, Massachusetts, United States, North America | www.perkinelmer.com |
U.S. clinical oncology next generation sequencing ngs market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Clinical Oncology Next Generation Sequencing Market will help companies and investors design strategic landscapes.
Targeted Sequencing And Resequencing was the largest segment with a revenue share of 72.75% in 2025.
Horizon Databook has segmented the U.S. clinical oncology next generation sequencing market based on whole genome sequencing, targeted sequencing and resequencing, whole exome sequencing covering the revenue growth of each sub-segment from 2021 to 2033.
- U.S. Clinical Oncology Next Generation Sequencing Market Technology Outlook (Revenue, USD Million , 2021-2033)
- Whole Exome Sequencing
- Targeted Sequencing and Resequencing
- Whole Genome Sequencing
- U.S. Clinical Oncology Next Generation Sequencing Market Workflow Outlook (Revenue, USD Million , 2021-2033)
- NGS Pre-Sequencing
- NGS Data Analysis
- NGS Sequencing
- U.S. Clinical Oncology Next Generation Sequencing Market Application Outlook (Revenue, USD Million , 2021-2033)
- Screening
- Companion Diagnostics
- Others
- U.S. Clinical Oncology Next Generation Sequencing Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Clinics
- Laboratories
Reasons to subscribe to clinical oncology next generation sequencing ngs market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of clinical oncology next generation sequencing ngs market databook
- Our clientele includes a mix of clinical oncology next generation sequencing ngs market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. clinical oncology next generation sequencing ngs market, including forecasts for subscribers. This country databook contains high-level insights into U.S. clinical oncology next generation sequencing ngs market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Clinical Oncology Next Generation Sequencing Market, 2021-2033 (US$M)
U.S. clinical oncology next generation sequencing ngs market statistics, by technology, 2021-2033 (US$M)
